A sponsor focused guide to clinical trials in Taiwan, covering TFDA regulation, patient access, leading research sites, therapeutic strengths, national health data infrastructure, and Taiwan's strategic role in Asia Pacific drug development.
Taiwan is a high income clinical research market of approximately 23.5 million people, with most of its population concentrated along the western corridor and connected to major academic medical centres across Taipei, Taichung, Tainan, and Kaohsiung. Taipei, the capital, anchors Taiwan's research ecosystem in the north, alongside Taoyuan and New Taipei City. Taichung is the central hub, while Tainan; Taiwan's historic capital; and Kaohsiung form the major southern research centres. All four metropolitan regions host internationally recognized academic medical centres with active Phase I; IV trial portfolios and deep investigator networks spanning every major therapeutic area.
Clinical trials are regulated by the Taiwan Food and Drug Administration (TFDA) under the Ministry of Health and Welfare (MOHW), operating under the Pharmaceutical Affairs Act and aligned GCP regulations. Taiwan achieved full ICH regulatory membership in 2018; the first in Asia to reach this status; formally harmonizing its standards with the US FDA, EMA, and PMDA and positioning it as the region's highest-credibility regulatory environment for global sponsors. Taiwan's clinical trial market has grown steadily under sustained government investment in biotechnology, with the MOHW's Clinical Trial Promotion Program channelling significant resources into site infrastructure, investigator training, and CRO ecosystem development across the island's major academic medical centres.
Taiwan's population is approximately 95% Han Chinese; predominantly Hoklo (~70%) and Hakka (~15%); with 16 recognized indigenous Austronesian peoples (~2.3%) whose distinct genetic lineages are of growing interest for population genomics and pharmacogenomics research. The overall ethnic homogeneity of the Han Chinese majority creates a strategically valuable patient cohort for trials targeting diseases with strong East Asian genetic associations: EGFR-activating mutations in non-small cell lung cancer, HBV-driven hepatocellular carcinoma, and metabolic phenotypes linked to East Asian ancestry. Literacy stands at approximately 98.5%, and English proficiency among medical investigators is high; the majority of Taiwan's research-active physicians have completed training or fellowship placements at US, European, or Japanese institutions.
Taiwan's disease burden reflects a high-income, rapidly aging population. Cancer has been the leading cause of death for more than four consecutive decades, with liver cancer, lung cancer, colorectal cancer, and breast cancer driving the majority of oncology trial activity. The national prevalence of Type 2 diabetes is approximately 11%, with metabolic syndrome and non-alcoholic fatty liver disease (NAFLD/MAFLD) highly prevalent; reflecting dietary and demographic transitions. Cardiovascular disease is the second-leading mortality driver. Critically, Taiwan's National Health Insurance (NHI) system; in place since 1995 and covering 99.9% of the population; maintains a comprehensive, longitudinally linked electronic health record database (the NHIRD) that enables precision patient identification, protocol-matched recruitment, and post-trial follow-up at a scale and data quality unmatched anywhere else in Asia.
The EGFR advantage: Approximately 50; 60% of Taiwanese patients with non-small cell lung cancer (NSCLC) adenocarcinoma carry EGFR-activating mutations; three to four times the rate observed in Western European and North American populations. For sponsors developing EGFR-targeted therapies, next-generation TKIs, or resistance-mechanism studies, Taiwan's investigator community is the deepest, most experienced, and best-characterized in the world. No other market matches the combination of patient depth, investigator expertise, and NHI-linked longitudinal data quality for this indication.
Taiwan's clinical research proposition is built on precision, credibility, and data quality: ICH-equivalent regulatory standards, a uniquely data-rich national health infrastructure, world-leading investigator depth in oncology and hepatology, and a government actively investing in positioning Taiwan as Asia's foremost clinical research destination. For sponsors pursuing a first-in-Asia strategy, Taiwan is not just a trial site; it is a regulatory and scientific platform whose data is recognized by every major global health authority.
Full ICH regulatory membership since 2018; standards fully harmonized with US FDA, EMA, and PMDA; TFDA CTA review timelines among the fastest in Asia; MOHW expedited review pathways for innovative oncology and rare disease products; Taiwan approvals widely recognized in pan-Asian regulatory submissions.
Per-patient and site operational costs significantly below Japan, Australia, and South Korea; competitive investigator fees relative to other high-standard Asian markets; MOHW clinical trial subsidy programs for innovative drugs; strong IP protection environment and stable political infrastructure supporting long-horizon sponsor investment.
50; 60% EGFR mutation prevalence in NSCLC; unmatched globally; one of the world's highest HCC incidence rates (~28 per 100,000); large treatment-naive pools in first-line oncology; NHI electronic records enabling precision patient identification; high trial compliance driven by an educated, health-literate population.
Network of internationally accredited academic medical centres; NHI Research Database (NHIRD); one of the world's largest linked health datasets; Taiwan Biobank with 200,000+ participants; ITRI and Academia Sinica biotech ecosystem; all major global CROs (IQVIA, ICON, Parexel, PPD) with established Taiwan operations.
Oncology is Taiwan's defining strength; driven by some of the world's highest rates of hepatocellular carcinoma and EGFR-mutant lung cancer, alongside significant burdens of colorectal, gastric, and breast cancer. Taiwan's investigator community has accumulated decades of Phase I; III trial experience in targeted therapies and immuno-oncology, producing clinical data trusted by the FDA, EMA, and PMDA alike. Hepatology is a natural complement: Taiwan's historically elevated HBV prevalence (among the highest in Asia prior to the 1984 universal vaccination program) has produced deep investigator expertise in viral hepatitis, cirrhosis, NASH/MAFLD, and HCC; a therapeutic nexus increasingly central to global drug development pipelines. Rare diseases are a growing priority underpinned by Taiwan's comprehensive Rare Disease Act (2000), one of Asia's most progressive orphan drug frameworks, and the National Taiwan University rare disease registry. Metabolic disease, cardiovascular outcomes, and neurology round out a broad and well-resourced portfolio.
Trial activity is distributed across Taiwan's western corridor; Taipei and its satellite cities (Taoyuan, New Taipei) dominate, accounting for the majority of Phase I and early-phase oncology work. Taichung is a growing secondary hub with two major academic medical centres, while Tainan and Kaohsiung provide strong Phase II; IV coverage in southern Taiwan. The Chang Gung Medical Foundation system, with campuses from Keelung to Kaohsiung, operates the largest single hospital network in Taiwan and one of the most active commercial trial portfolios in Asia. Linkou Chang Gung Memorial Hospital is the largest hospital in Taiwan by bed count.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | National Taiwan University Hospital (NTUH) | Taipei | Taiwan's flagship academic hospital and the country's premier clinical research institution; NTU College of Medicine affiliate; the oldest and most prestigious medical faculty in Taiwan; Phase I; IV across oncology, hepatology, haematology, cardiovascular, and rare diseases; extensive international sponsor relationships and one of Asia's most active Phase I units. |
| 02 | Taipei Veterans General Hospital (TVGH) | Taipei | One of Taiwan's top five hospitals by research output; National Yang-Ming Chiao Tung University (NYCU) affiliate; Phase II; IV portfolio spanning oncology, gastroenterology, cardiology, and neurology; particularly strong in lung cancer and hepatocellular carcinoma research; active participant in international multi-centre trial networks. |
| 03 | Linkou Chang Gung Memorial Hospital | Linkou | The largest hospital in Taiwan by bed count and one of the largest in Asia; Chang Gung University affiliate; flagship campus of the Chang Gung Medical Foundation network; Phase I; IV across oncology, liver disease, cardiovascular, and paediatrics; one of the highest-enrolling commercial trial sites in the Asia-Pacific region. |
| 04 | Tri-Service General Hospital (TSGH) | Taipei | National Defense Medical Center affiliate; major academic hospital with strong oncology, infectious disease, and internal medicine research programs; Phase II; IV commercial portfolio; GCP-accredited research infrastructure serving both civilian and military patient populations across the greater Taipei metropolitan area. |
| 05 | Taichung Veterans General Hospital (TCVGH) | Taichung | Central Taiwan's leading academic hospital and a major anchor for the region's clinical research network; NYCU affiliate; Phase II; IV across oncology, cardiology, endocrinology, and nephrology; one of Taiwan's top enrollers for cardiovascular outcomes trials and metabolic disease studies. |
| 06 | China Medical University Hospital (CMUH) | Taichung | China Medical University affiliate; one of central Taiwan's most active commercial trial sites; Phase II; IV oncology, hepatology, and internal medicine portfolio; notable for integrative medicine research alongside conventional pharmaceutical trials; strong site management infrastructure and experienced investigator team. |
| 07 | National Cheng Kung University Hospital (NCKUH) | Tainan | Southern Taiwan's premier academic medical centre and NCKU College of Medicine affiliate; Phase II; IV across oncology, infectious disease, rheumatology, and cardiovascular disease; geographically positioned to capture southern Taiwanese patient populations distinct from the Taipei metropolitan catchment; active international sponsor and investigator-initiated trial portfolio. |
| 08 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | Kaohsiung Medical University affiliate and southern Taiwan's most research-active institution; Phase II; IV oncology, hepatology, and nephrology trials; particular strength in liver cancer and viral hepatitis research reflecting the historical HBV burden in southern Taiwan; active Phase III commercial portfolio with international CRO partnerships. |
| 09 | Kaohsiung Veterans General Hospital (KVGH) | Kaohsiung | NYCU affiliate and a major research hospital serving southern Taiwan; Phase II; IV oncology, pulmonology, and gastroenterology trials; strong lung cancer investigator team with deep EGFR-targeted therapy trial experience; complements KMUH to provide multi-site coverage across the greater Kaohsiung metropolitan area. |
| 10 | Chang Gung Memorial Hospital | Kaohsiung | Southern campus of the Chang Gung Medical Foundation network; Chang Gung University affiliate; Phase II; IV oncology, cardiovascular, and metabolic disease trials; extends the CGMF network's national enrollment reach into southern Taiwan; consistent high enrollment performance across multi-centre commercial trial programs. |
| 11 | Mackay Memorial Hospital | Taipei | One of Taiwan's oldest and most internationally recognized mission hospitals; Phase II; IV trials across oncology, cardiology, and infectious disease; strong institutional GCP compliance culture and established relationships with US and European sponsors; Mackay Medical College affiliate with active investigator training programs. |
Taiwan's flagship academic hospital and the country's premier clinical research institution; NTU College of Medicine affiliate; the oldest and most prestigious medical faculty in Taiwan; Phase I; IV across oncology, hepatology, haematology, cardiovascular, and rare diseases; extensive international sponsor relationships and one of Asia's most active Phase I units.
One of Taiwan's top five hospitals by research output; National Yang-Ming Chiao Tung University (NYCU) affiliate; Phase II; IV portfolio spanning oncology, gastroenterology, cardiology, and neurology; particularly strong in lung cancer and hepatocellular carcinoma research; active participant in international multi-centre trial networks.
The largest hospital in Taiwan by bed count and one of the largest in Asia; Chang Gung University affiliate; flagship campus of the Chang Gung Medical Foundation network; Phase I; IV across oncology, liver disease, cardiovascular, and paediatrics; one of the highest-enrolling commercial trial sites in the Asia-Pacific region.
National Defense Medical Center affiliate; major academic hospital with strong oncology, infectious disease, and internal medicine research programs; Phase II; IV commercial portfolio; GCP-accredited research infrastructure serving both civilian and military patient populations across the greater Taipei metropolitan area.
Central Taiwan's leading academic hospital and a major anchor for the region's clinical research network; NYCU affiliate; Phase II; IV across oncology, cardiology, endocrinology, and nephrology; one of Taiwan's top enrollers for cardiovascular outcomes trials and metabolic disease studies.
China Medical University affiliate; one of central Taiwan's most active commercial trial sites; Phase II; IV oncology, hepatology, and internal medicine portfolio; notable for integrative medicine research alongside conventional pharmaceutical trials; strong site management infrastructure and experienced investigator team.
Southern Taiwan's premier academic medical centre and NCKU College of Medicine affiliate; Phase II; IV across oncology, infectious disease, rheumatology, and cardiovascular disease; geographically positioned to capture southern Taiwanese patient populations distinct from the Taipei metropolitan catchment; active international sponsor and investigator-initiated trial portfolio.
Kaohsiung Medical University affiliate and southern Taiwan's most research-active institution; Phase II; IV oncology, hepatology, and nephrology trials; particular strength in liver cancer and viral hepatitis research reflecting the historical HBV burden in southern Taiwan; active Phase III commercial portfolio with international CRO partnerships.
NYCU affiliate and a major research hospital serving southern Taiwan; Phase II; IV oncology, pulmonology, and gastroenterology trials; strong lung cancer investigator team with deep EGFR-targeted therapy trial experience; complements KMUH to provide multi-site coverage across the greater Kaohsiung metropolitan area.
Southern campus of the Chang Gung Medical Foundation network; Chang Gung University affiliate; Phase II; IV oncology, cardiovascular, and metabolic disease trials; extends the CGMF network's national enrollment reach into southern Taiwan; consistent high enrollment performance across multi-centre commercial trial programs.
One of Taiwan's oldest and most internationally recognized mission hospitals; Phase II; IV trials across oncology, cardiology, and infectious disease; strong institutional GCP compliance culture and established relationships with US and European sponsors; Mackay Medical College affiliate with active investigator training programs.
These are the primary regulatory, academic, and industry bodies shaping Taiwan's clinical research ecosystem.
Taiwan's national competent authority for clinical trial regulation and medicinal product approval; operates under full ICH membership with standards harmonized to US FDA, EMA, and PMDA; recognized internationally for regulatory quality and transparency; TFDA data accepted as primary evidence in pan-Asian regulatory submissions.
Strategic oversight body for Taiwan's healthcare system and clinical research policy; operates the Clinical Trial Promotion Programme; a sustained government investment in site infrastructure, investigator training, and CRO ecosystem development; coordinates the National Health Insurance system underpinning Taiwan's world-class patient data infrastructure.
Taiwan's national applied research institute and the primary government vehicle for translating biomedical research into clinical and commercial applications; operates biomarker development, digital health, and medical device trial support programs; strategic partner to both domestic biotech companies and international sponsors entering the Taiwan market.
Taiwan's oldest and most prestigious medical faculty and the primary driver of the national investigator pipeline; affiliated with NTUH and the NTU Cancer Center; produces the majority of Taiwan's internationally published clinical researchers and GCP-certified investigators across all major therapeutic areas.
Taiwan's national biomedical research institute, established by MOHW to bridge basic science and clinical application; operates national cancer, chronic disease, and population genomics research programs; coordinates Taiwan's clinical trial network infrastructure and serves as the scientific backbone for investigator-initiated multi-centre studies.
Taiwan's highest national research academy; the Institute of Biomedical Sciences and Genomics Research Center are world-leading centres for molecular biology, cancer genomics, and pharmacogenomics; foundational research here directly informs the biomarker-driven trial designs deployed across Taiwan's academic medical centres.
One of Taiwan's leading private medical universities, operating a three-hospital system (TMUH, Wan Fang, Shuang Ho) with active trial portfolios; TMU's clinical research enterprise is particularly strong in oncology biomarker development, metabolic disease, and digital health trial methodology.
Global CRO with well-established Taiwan operations; Phase I; IV trial management across all major therapeutic areas; TFDA regulatory submission expertise and NHIRD data analytics capability; site monitoring and data management across all major Taiwan academic medical centres.
International CRO with Taiwan office managing Phase I; IV oncology, rare disease, and metabolic disease trials; deep TFDA regulatory expertise and established investigator relationships at NTUH, TVGH, and the Chang Gung network; strong early-phase and biomarker-driven trial capability.
Global CRO with Taiwan operations specializing in regulatory strategy, Phase II; III trial management, and market access planning; TFDA submission expertise supporting first-in-Asia regulatory strategies for US and European sponsors; oncology and metabolic disease therapeutic area depth across Taiwan's academic site network.
Taiwan's national biotechnology industry association, representing over 350 member companies and actively promoting Taiwan as a destination for international clinical research partnerships; coordinates public-private initiatives linking global sponsors, domestic CROs, academic medical centres, and government research programs.
Taiwan offers one of Asia Pacific's most complete clinical research environments; the only market in the region that combines full ICH regulatory membership, a 99.9%-covered national health system with decades of linked electronic health records, world-leading investigator depth in EGFR-positive lung cancer and hepatocellular carcinoma, and per-patient costs that are meaningfully below Japan and South Korea. For sponsors pursuing a first-in-Asia regulatory strategy, Taiwan's TFDA data is recognized as primary evidence by the FDA, EMA, and PMDA; making a Taiwan trial not just a regional effort but a global regulatory asset. The NHI database enables precision patient recruitment and protocol-matched enrollment at a scale no other Asian market can replicate. The Taiwan Biobank is approaching 200,000 participants. Academia Sinica and the NHRI anchor a world-class translational science ecosystem. And a government that has consistently backed clinical research with funding, infrastructure, and regulatory modernization shows no sign of slowing. For sponsors who need rigorous data, expert investigators, Asian patient populations, and a regulatory framework the world trusts; Taiwan delivers all four.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.